arrow
K

Katarzyna Pogoda

Maria Sklodowska-Curie National Research Institute of Oncology
H指数:18
被引数:1,623

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)

转移性乳腺癌患者关注的生活质量问题:欧洲癌症研究与治疗组织转移性乳腺癌模块(EORTC QLQ-MBR)的第一阶段和第二阶段开发

Breast
IF7.9
2026-09-050
OA
Developing thresholds for clinical importance for the EORTC Quality of Life Questionnaire-Elderly 14 (QLQ-ELD14) to improve its interpretation in clinical practice and research

为EORTC生活质量问卷-老年14(QLQ-ELD14)制定临床重要性阈值,以改进其在临床实践和研究中的解释

2026-08-010
OAAI
Chemotherapy Type and Survival in Young BRCA1/2 Carriers With HER2-Negative Early Breast Cancer

BRCA1/2携带者中HER2阴性早期乳腺癌年轻患者的化疗类型与生存期

2026-07-140
OA
De-Escalated Chemotherapy and Endocrine Therapy Outcomes in Young Women with Stage I HR+/HER2+ Breast Cancer: An International Real-World Study.

在年轻女性中,针对I期HR+/HER2+乳腺癌的降级化疗和内分泌治疗效果:一项国际真实世界研究。

2026-06-110
OAAI
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+breast cancer: An international real-world study.

年轻女性中I期HR+/HER2+乳腺癌降级化疗和内分泌治疗效果:一项国际真实世界研究

2026-06-010
PRE
Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study

BRCA1/2携带者早期乳腺癌患者的放射治疗管理:一项国际队列研究

2026-04-040
OAAI
Assessing Quality of Life in Individuals with Hereditary Cancer Risk: Results from Phases 1-3a of the EORTC QLQ-HCR30 Questionnaire

评估具有遗传性癌症风险个体的生活质量:EORTC QLQ-HCR30问卷第1-3a阶段的结果

2026-01-090
OAAI
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.

辅助性卵巢功能抑制和芳香化酶抑制剂在激素受体和HER2阳性乳腺癌绝经前患者中的应用,按化疗和曲妥珠单抗的时机及新辅助治疗的反应。

2025-12-060
OAAI
REAL-WORLD OUTCOMES WITH PALBOCICLIB, RIBOCICLIB, AND ABEMACICLIB PLUS ENDOCRINE THERAPY IN HR+/HER2− ADVANCED BREAST CANCER: A MULTICENTER RETROSPECTIVE STUDY

真实世界研究中,PALBOCICLIB、RIBOCICLIB和ABEMACICLIB联合内分泌疗法在HR+/HER2−晚期乳腺癌中的疗效:一项多中心回顾性研究

2025-11-240
OAAI
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY

年轻乳腺癌患者BRCA1/2致病性或可能致病性变异的类型和位置与表型和预后之间的关系: 一项国际队列研究的结果

2025-11-170
OAAI
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers

年轻BRCA携带者在孕期被诊断患有乳腺癌后,再次怀孕的安全性

2025-08-130
OAAI
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

风险降低手术与年轻BRCA携带者乳腺癌患者生存期的关联:一项国际队列研究

2025-05-080
PRE
Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha

白细胞介素-6在蒽环类药物相关心脏功能障碍中的作用:与髓过氧化物酶和TNF-Alpha的比较

2025-04-250
OA
An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42

国际IV期实地研究-评估乳腺癌EORTC QLQ-BR42患者生活质量的更新模块的心理计量学特性

BREAST
IF7.9
2025-04-010
OAAI
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
2024-10-010
OAAI